

**BAXTER INTERNATIONAL INC.**  
**Sales by Franchise**  
**Periods Ending June 30, 2014 and 2013**  
**(unaudited)**  
**(\$ in millions)**

	<b>Q2 2014</b>	<b>Q2 2013</b>	<b>% Growth @ Actual Rates</b>	<b>% Growth @ Constant Rates</b>	<b>YTD 2014</b>	<b>YTD 2013</b>	<b>% Growth @ Actual Rates</b>	<b>% Growth @ Constant Rates</b>
<b>BioScience</b>								
Hemophilia	\$904	\$849	6%	6%	\$1,731	\$1,614	7%	7%
BioTherapeutics	548	513	7%	6%	1,050	1,022	3%	2%
BioSurgery	189	178	6%	5%	365	350	4%	4%
Vaccines	110	98	12%	6%	213	182	17%	15%
<b>Total BioScience</b>	<b>\$1,751</b>	<b>\$1,638</b>	<b>7%</b>	<b>6%</b>	<b>\$3,359</b>	<b>\$3,168</b>	<b>6%</b>	<b>6%</b>
<b>Medical Products</b>								
Fluid Systems	\$816	\$755	8%	8%	\$1,573	\$1,495	5%	6%
Renal <sup>1</sup>	1,044	654	60%	61%	2,035	1,244	64%	66%
Specialty Pharmaceuticals	404	366	10%	9%	771	729	6%	6%
BioPharma Solutions	249	256	(3%)	(4%)	477	481	(1%)	0%
<b>Total Medical Products</b>	<b>\$2,513</b>	<b>\$2,031</b>	<b>24%</b>	<b>24%</b>	<b>\$4,856</b>	<b>\$3,949</b>	<b>23%</b>	<b>24%</b>
<b>Total Baxter</b>	<b>\$4,264</b>	<b>\$3,669</b>	<b>16%</b>	<b>16%</b>	<b>\$8,215</b>	<b>\$7,117</b>	<b>15%</b>	<b>16%</b>

<sup>1</sup> Consists of PD and HD therapies, and includes Gambro net sales of \$408 million in the second quarter of 2014 and \$808 million for the six months ended June 30, 2014. Renal sales excluding Gambro decreased by 3% at actual rates and 1% at constant rates during the second quarter of 2014. Renal sales excluding Gambro decreased by 1% at actual rates and grew by 1% at constant rates for the six months ended June 30, 2014.